Workflow
Neurodegeneration treatment
icon
Search documents
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock
Globenewswire· 2025-10-15 21:15
Core Viewpoint - Annovis Bio, Inc. has successfully closed a registered direct offering, raising approximately $6 million to support its operations in developing therapies for neurodegenerative diseases like Alzheimer's and Parkinson's disease [1][2]. Group 1: Offering Details - The company offered 4,000,000 shares of common stock at a price of $1.50 per share [1]. - H.C. Wainwright & Co. served as the exclusive placement agent for this offering [2]. - The gross proceeds from the offering were around $6 million, which will be used for working capital and general corporate purposes [2]. Group 2: Regulatory Information - The securities were sold under a "shelf" registration statement on Form S-3, which was filed with the SEC on February 1, 2024, and declared effective on February 12, 2024 [3]. - A prospectus supplement related to the offering was filed with the SEC and is available on their website [3]. Group 3: Company Overview - Annovis Bio is headquartered in Malvern, Pennsylvania, and focuses on innovative therapies for neurodegenerative diseases [5]. - The company aims to improve patient outcomes and quality of life through its research and development efforts [5].
Alector, Inc. - Special Call
Seeking Alpha· 2025-09-23 01:03
Group 1 - The event will feature an overview from Dr. Sara Kenkare-Mitra, President and Head of Research and Development, focusing on Alector's multistage pipeline and strategies for addressing neurodegeneration [3] - Alector will highlight its progranulin elevating franchise in frontotemporal dementia with GRN mutations (FTD-GRN) and Alzheimer's disease, specifically discussing the development of latozinemab and nivisnebart (formerly AL101) in collaboration with GSK [3]
Inhibikase Therapeutics(IKT) - Prospectus
2023-02-02 02:02
Table of Contents As filed with the Securities and Exchange Commission on February 1, 2023. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INHIBIKASE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 26-3407249 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Iden ...